Pirfenidone

Status
Phase 3
Condition
Sarcoidosis ILD
Intervention Type
Oral Drug
Funder Type
Organization | University

Drug Details

Pirfenidone (Esbriet®, Pirfenex®, Pirespa®): Pirfenidone is an antifibrotic and anti-inflammatory drug approved to treat IPF in the US, Europe, Canada, Asia, and Australia. In clinical trials, pirfenidone has been shown to slow progression of mild-to-moderate idiopathic pulmonary fibrosis. It is taken by mouth three times a day. 

Study Purpose

Study comparing pirfenidone versus placebo for patients with advanced fibrotic sarcoidosis.

Find a Clinical Trial


footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >